A prospective, multi-centre, open-label study to establish the equipotent dose ratio after switching from [the remainder of this trial title is not currently available]
Phase of Trial: Phase IV
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Buprenorphine (Primary) ; Morphine
- Indications Cancer pain
- Focus Therapeutic Use
- 06 Nov 2016 Status changed to discontinued.
- 09 Nov 2012 Additional lead trial centre identified as reported by EudraCT.
- 09 Nov 2012 Planned number of patients changed from 10 to 180 as reported by EudraCT.